Clene
1D
1W
1M
3M
YTD
1Y
5Y
ALL
Why Robinhood?
Robinhood gives you the tools you need to put your money in motion. You can buy or sell Clene and other ETFs, options, and stocks.About CLNN
Clene, Inc. is a clinical-stage biopharmaceutical company, which focuses on the discovery, development, and commercialization of novel clean-surfaced nanotechnology therapeutics. It offers a nanotechnology drug platform for the development of a new class of orally administered neurotherapeutic drugs.
CEORobert Dee Etherington
CEORobert Dee Etherington
Employees76
Employees76
HeadquartersSalt Lake City, Utah
HeadquartersSalt Lake City, Utah
Founded2013
Founded2013
Employees76
Employees76
CLNN Key Statistics
Market cap109.16M
Market cap109.16M
Price-Earnings ratio-4.20
Price-Earnings ratio-4.20
Dividend yield—
Dividend yield—
Average volume158.11K
Average volume158.11K
High today—
High today—
Low today—
Low today—
Open price$11.55
Open price$11.55
Volume100.00
Volume100.00
52 Week high$13.50
52 Week high$13.50
52 Week low$2.28
52 Week low$2.28
Stock Snapshot
The current Clene(CLNN) stock price is $10.71, with a market capitalization of 109.16M. The stock trades at a price-to-earnings (P/E) ratio of -4.20.
On 2025-11-05, Clene(CLNN) stock opened at $11.55, reached a high of —, and a low of —.
Clene(CLNN) shares are trading with a volume of 100, against a daily average of 158.11K.
In the last year, Clene(CLNN) shares hit a 52-week high of $13.50 and a 52-week low of $2.28.
In the last year, Clene(CLNN) shares hit a 52-week high of $13.50 and a 52-week low of $2.28.
Analyst ratings
100%
of 7 ratingsBuy
100%
Hold
0%
Sell
0%
People also own
Based on the portfolios of people who own CLNN. This list is generated using Robinhood data, and it’s not a recommendation.